贝瑞基因收盘上涨1.19%，最新市净率2.53，总市值42.18亿元

Core Viewpoint - Berry Genomics has shown a slight increase in stock price and has a market capitalization of 4.218 billion yuan, with a net asset ratio of 2.53, indicating a stable financial position despite recent revenue declines [1]. Company Overview - Berry Genomics specializes in gene testing services based on high-throughput sequencing technology, along with the sale of related equipment and reagents [1]. - The company offers a comprehensive solution of "products + services" to hospitals and third-party medical laboratories, establishing a leadership position in the genetics field [1]. - The proprietary cSMART liquid biopsy technology, which has a resolution of 10,000, has received domestic and international patents, solidifying the company's leading position in oncology [1]. Shareholder Information - As of March 31, 2025, Berry Genomics has 63,808 shareholders, an increase of 19,482 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]. Financial Performance - In the first quarter of 2025, the company reported revenue of 218 million yuan, a year-on-year decrease of 22.08%, and a net loss of approximately 6.46 million yuan, representing a year-on-year decline of 178.47% [1]. - The gross profit margin for the company stands at 49.48% [1]. Industry Comparison - Berry Genomics has a TTM PE ratio of -20.36 and a static PE ratio of -21.92, with a market capitalization of 4.218 billion yuan, which is below the industry average PE of 47.74 and the industry median PE of 36.15 [2]. - The company’s price-to-book ratio of 2.53 is also lower than the industry average of 4.40 [2].